Recent Updates — NKTR

On October 1, 2026, Nektar Therapeutics released new data from its Phase 2b REZOLVE-AA clinical trial for alopecia areata and announced the initiation of a third Phase 3 study in atopic dermatitis. The Phase 3 ZENITH AA study for alopecia areata is scheduled to begin in early 2027, enrolling 850 patients with severe-to-very-severe disease. Clinical results showed that 63% of patients maintained a SALT Score ≤20 six months after stopping treatment, and the proportion achieving near-complete hair regrowth (SALT ≤10) doubled from 7% to 19% during this off-treatment period. Nektar Therapeutics is a clinical-stage biotechnology company developing treatments for autoimmune and chronic inflammatory diseases.

On September 24, 2026, a jury in the U.S. District Court for the Northern District of California found Eli Lilly and Company liable for breaching the implied covenant of good faith and fair dealing under their license agreement for rezpegaldesleukin. The jury awarded Nektar Therapeutics $90 million in damages plus interest to be determined by the court. This verdict is subject to post-trial proceedings and potential appeal. Nektar Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.

Nektar Therapeutics reported financial results for the quarter ended June 30, 2026. Revenue was $10.1 million compared to $11.2 million in the prior year period. The company reported a net loss of $40.6 million, or $1.23 per share, versus a net loss of $41.6 million, or $2.95 per share, in the same quarter last year. Cash and investments increased to $1,023.4 million from $245.8 million at year-end 2025, primarily due to a public offering completed in April 2026 that raised $373.8 million in gross proceeds. The company initiated Phase 3 trials for its lead drug rezpegaldesleukin in atopic dermatitis and plans to begin studies in alopecia areata in early 2027. Nektar Therapeutics is a clinical-stage biotechnology company focused on developing immunology therapies.